KR20040041612A - 합성 씨형 간염 바이러스 엔벨롭 단백질 및 그 백신 용도 - Google Patents

합성 씨형 간염 바이러스 엔벨롭 단백질 및 그 백신 용도 Download PDF

Info

Publication number
KR20040041612A
KR20040041612A KR10-2004-7003715A KR20047003715A KR20040041612A KR 20040041612 A KR20040041612 A KR 20040041612A KR 20047003715 A KR20047003715 A KR 20047003715A KR 20040041612 A KR20040041612 A KR 20040041612A
Authority
KR
South Korea
Prior art keywords
hcv
protein
composition
majority
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR10-2004-7003715A
Other languages
English (en)
Korean (ko)
Inventor
루이스 네빌레
아리에 자우베르만
Original Assignee
엑스티엘 바이오파마수티칼즈 엘티디.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엑스티엘 바이오파마수티칼즈 엘티디. filed Critical 엑스티엘 바이오파마수티칼즈 엘티디.
Publication of KR20040041612A publication Critical patent/KR20040041612A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
    • C07K16/118—Hepatitis C virus; GB virus C [GBV-C]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR10-2004-7003715A 2001-09-13 2002-09-09 합성 씨형 간염 바이러스 엔벨롭 단백질 및 그 백신 용도 Withdrawn KR20040041612A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL145440 2001-09-13
IL14544001A IL145440A0 (en) 2001-09-13 2001-09-13 Synthetic hcv envelope proteins and their use for vaccination
PCT/IL2002/000744 WO2003022880A2 (en) 2001-09-13 2002-09-09 Synthetic hcv envelope proteins and their use for vaccination

Publications (1)

Publication Number Publication Date
KR20040041612A true KR20040041612A (ko) 2004-05-17

Family

ID=11075784

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2004-7003715A Withdrawn KR20040041612A (ko) 2001-09-13 2002-09-09 합성 씨형 간염 바이러스 엔벨롭 단백질 및 그 백신 용도

Country Status (8)

Country Link
US (1) US20050069865A1 (https=)
EP (1) EP1427827A2 (https=)
JP (1) JP2005510211A (https=)
KR (1) KR20040041612A (https=)
CN (1) CN1555415A (https=)
CA (1) CA2460509A1 (https=)
IL (1) IL145440A0 (https=)
WO (1) WO2003022880A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1846439A2 (en) * 2005-01-31 2007-10-24 The Johns Hopkins University Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
EP2061805B1 (en) 2006-08-25 2020-02-12 Macfarlane Burnet Institute for Medical Research and Public Health Limited Recombinant hcv e2 glycoprotein
US9758794B2 (en) * 2008-04-22 2017-09-12 Rutgers, The State University Of New Jersey HCV E2 construct compositions and methods
WO2009146902A1 (en) * 2008-06-03 2009-12-10 Okairòs Ag A vaccine for the prevention and therapy of hcv infections
US9512184B2 (en) 2011-05-20 2016-12-06 Emory University Hepatitis C virus particles, vaccines, compositions and methods related thereto
CN105330730A (zh) * 2014-07-29 2016-02-17 中国科学院上海巴斯德研究所 一种丙型肝炎病毒重组蛋白的制备及其应用
CN116768983A (zh) * 2020-10-28 2023-09-19 王立良 一种用于慢性乙型肝炎预防和/或治疗的蛋白、编码基因、重组腺相关病毒及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849987A (en) * 1992-06-02 1998-12-15 Yeda Research And Development Co. Ltd. Animal model for hepatitis virus infection

Also Published As

Publication number Publication date
EP1427827A2 (en) 2004-06-16
JP2005510211A (ja) 2005-04-21
IL145440A0 (en) 2002-06-30
CA2460509A1 (en) 2003-03-20
US20050069865A1 (en) 2005-03-31
CN1555415A (zh) 2004-12-15
WO2003022880A3 (en) 2003-10-09
WO2003022880A2 (en) 2003-03-20

Similar Documents

Publication Publication Date Title
JP3892443B2 (ja) 診断用及び治療用の精製ｃ型肝炎ウイルスエンベロープ蛋白
CA2065287C (en) New hcv isolates
CN111848786B (zh) 一种单克隆抗体、其制备方法及用途
JP2009232863A (ja) Ｃ型肝炎のｅ１およびｅ２短縮型ポリペプチドの細胞内生成
IE83377B1 (en) New HCV isolate J-1
JP2002528140A (ja) ヒトｐａｎ−ｈｃｖヒトモノクローナル抗体
CN109182380B (zh) 杆状病毒表达的猪瘟e2亚单位疫苗的制备方法及应用
JP5681337B2 (ja) Ｅ型肝炎ウイルスのポリペプチド断片、それを含むワクチン組成物及び診断キット、並びにその使用
JPH08504096A (ja) Ｅ型肝炎パキスタン株の組換えタンパク質ならびに診断法およびワクチンにおけるそれらの利用
JP2007513604A (ja) 新規エンテロウイルス、ワクチン、医薬および診断キット
JPH11506328A (ja) 単離された、プロセシングされていないポリペプチドを使用するプラス鎖ｒｎａウイルスの診断およびプラス鎖ｒｎａウイルスに対するワクチン接種
US6682909B2 (en) Immunogenic composition of hepatitis C and methods of use thereof
KR20040041612A (ko) 합성 씨형 간염 바이러스 엔벨롭 단백질 및 그 백신 용도
JP4641695B2 (ja) 新規なｈｅｖ抗原性ペプチド及び方法
CN105085672A (zh) 3d蛋白特异性单克隆免疫球蛋白a抗体及其组合物
CN100497377C (zh) Sars冠状病毒结构蛋白orf3及其应用
US20040234542A1 (en) Recombinant orf2 proteins of the swine hepatitis e virus and their use as a vaccine and as a diagnostic reagent for medical and veterinary applications
AU2002329033A1 (en) Synthetic HCV envelope proteins and their use for vaccination
Timofeev et al. A study of the NS3 nonstructural protein of tick-borne encephalitis virus using monoclonal antibodies against the virus
JPH08504421A (ja) Ｈｃｖのｃ３３領域由来のペプチド、該ペプチドに対する抗体及びｈｃｖの検出方法
Park et al. Characterization of Monoclonal Antibody Specific for Hepatitis C Virus E2 Envelope Protein
JP2004525885A (ja) 診断用および治療用の精製ｃ型肝炎ウイルスエンベロープタンパク質

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20040312

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid